


We claim:

1. A compounds in accord with formula I:




I

5 wherein:

- R<sup>1</sup> at each occurrence is a moiety independently selected from CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, halogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, R<sup>a</sup>, R<sup>b</sup>, SR<sup>a</sup>, NR<sup>e</sup>R<sup>f</sup>, CH<sub>2</sub>NR<sup>e</sup>R<sup>f</sup>, OR<sup>c</sup>, and CH<sub>2</sub>OR<sup>c</sup>, where m is selected from 0, 1, 2 or 3; wherein R<sup>a</sup>, R<sup>b</sup>, and R<sup>c</sup> are independently at each occurrence selected from hydrogen, C<sub>1-6</sub>alkyl, C(O)R<sup>d</sup>, C(O)NHR<sup>d</sup> and CO<sub>2</sub>R<sup>d</sup>, or R<sup>a</sup> and R<sup>b</sup> may together be (CH<sub>2</sub>)<sub>j</sub>G(CH<sub>2</sub>)<sub>k</sub> or G(CH<sub>2</sub>)<sub>j</sub>G where G is oxygen, j is 1, 2, 3 or 4, k is 0, 1 or 2; where R<sup>d</sup> at each occurrence is independently selected from C<sub>1-6</sub>alkyl, and R<sup>e</sup> and R<sup>f</sup> are independently at each occurrence selected from hydrogen, C<sub>1-6</sub>alkyl, C(O)R<sup>d</sup>, C(O)NHR<sup>d</sup>, CO<sub>2</sub>R<sup>d</sup>;
- R<sup>2</sup> at each occurrence is independently selected from hydrogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, halogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, R<sup>a</sup>, R<sup>b</sup>, SR<sup>a</sup>, NR<sup>e</sup>R<sup>f</sup>, CH<sub>2</sub>NR<sup>e</sup>R<sup>f</sup>, OR<sup>c</sup>, and CH<sub>2</sub>OR<sup>c</sup>, where n is selected from 0, 1, 2 or 3; wherein R<sup>a</sup>, R<sup>b</sup>, and R<sup>c</sup> are independently at each occurrence selected from hydrogen, C<sub>1-6</sub>alkyl, C(O)R<sup>d</sup>, C(O)NHR<sup>d</sup> and CO<sub>2</sub>R<sup>d</sup>, or R<sup>a</sup> and R<sup>b</sup> may together be (CH<sub>2</sub>)<sub>j</sub>G(CH<sub>2</sub>)<sub>k</sub> or G(CH<sub>2</sub>)<sub>j</sub>G where G is oxygen, j is 1, 2, 3 or 4, k is 0, 1 or 2; where R<sup>d</sup> at each occurrence is independently selected from C<sub>1-6</sub>alkyl, and R<sup>e</sup> and R<sup>f</sup> are independently at each occurrence selected from hydrogen, C<sub>1-6</sub>alkyl, C(O)R<sup>d</sup>, C(O)NHR<sup>d</sup>, CO<sub>2</sub>R<sup>d</sup>;
- R<sup>3</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C(O)-(CH<sub>2</sub>)<sub>q</sub>-NR<sup>8</sup>R<sup>9</sup>, (CH<sub>2</sub>)<sub>r</sub>-NR<sup>8</sup>R<sup>9</sup>, (CH<sub>2</sub>)<sub>q</sub>-O-D, (CH<sub>2</sub>)<sub>q</sub>-D and (CH<sub>2</sub>)<sub>q</sub>-CH=CH-D, wherein R<sup>8</sup> and R<sup>9</sup> are independently selected from hydrogen and C<sub>1-6</sub>alkyl, q is selected from 1, 2 or 3, r is selected from 1, 2, 3 or 4 and D is selected from phenyl or indolyl which phenyl or indolyl may bear one or more substituents selected from halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy and -O-(CH<sub>2</sub>)<sub>q</sub>-O-;
- R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> at each occurrence are independently selected from hydrogen or C<sub>1-6</sub>alkyl, or

independently, R<sup>4</sup> and R<sup>5</sup> together with the carbon to which they are attached and R<sup>6</sup> and R<sup>7</sup> together with the carbon to which they are attached form a moiety in accord with formula II,



5 wherein p is selected from 0, 1, 2, 3 or 4;

*in vivo*-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

2. A compound according to Claim 1, wherein:

R<sup>1</sup> at each occurrence is independently selected from fluoro, cyano, C<sub>1-6</sub>alkyl and  
10 C<sub>1-6</sub>alkoxy and m is 1, 2 or 3;

R<sup>2</sup> at each occurrence is independently selected from halogen where n is 1 or 2, and  
R<sup>3</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl;

*in vivo*-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

15 3. A compound according to Claim 1, wherein:

R<sup>1</sup> at each occurrence is independently selected from fluoro, cyano, ethyl and methoxy  
and m is 1, 2 or 3;

R<sup>2</sup> at each occurrence is independently selected from halogen where n is 1 or 2, and  
R<sup>3</sup> is selected from hydrogen and methyl;

20 *in vivo*-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

4. A compound according to Claim 1, wherein R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each hydrogen and R<sup>7</sup> is  
methyl *in vivo*-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

25 5. A compound according to Claim 1, wherein:

R<sup>1</sup> at each occurrence is independently selected from fluoro, cyano, C<sub>1-6</sub>alkyl and  
C<sub>1-6</sub>alkoxy and m is 1, 2 or 3;

R<sup>2</sup> at each occurrence is independently selected from halogen where n is 1 or 2, and  
R<sup>3</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C(O)-(CH<sub>2</sub>)<sub>q</sub>-NR<sup>8</sup>R<sup>9</sup>, (CH<sub>2</sub>)<sub>r</sub>-NR<sup>8</sup>R<sup>9</sup>, (CH<sub>2</sub>)<sub>q</sub>-

30 O-D, wherein R<sup>8</sup> and R<sup>9</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkoxy,  
q is 1, 2 or 3, r is 1, 2, 3 or 4 and D is selected from phenyl, indol-3-yl, indol-4-yl which

phenyl may bear one or more substituents selected from fluoro, methyl, ethyl, methoxy, ethoxy or -O-(CH<sub>2</sub>)<sub>2</sub>-O- and which indolyl may bear one or more substituents selected from fluoro, methyl, ethyl, methoxy or ethoxy, *in vivo*-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

5

6. A pharmaceutical composition comprising a compound according to Claim 1 together with at least one pharmaceutically-acceptable excipient or diluent.

7. The pharmaceutical composition of Claim 6 for treating a disorder or condition  
10 selected from hypertension, depression, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, phobias, agoraphobia, social phobia, simple phobias,  
15 posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, anorexia nervosa, bulimia nervosa, obesity, chemical dependencies, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, dementia, amnestic disorders, age-related cognitive decline, Parkinson's diseases,  
20 dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, endocrine disorders, hyperprolactinaemia, vasospasm, spasm of the cerebral vasculature, cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention  
25 deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders, in a mammal, preferably a human, comprising an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.
- 30 8. A method of treating a disease condition wherein antagonism of NK<sub>1</sub> receptors in combination with SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or an *in vivo*-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.

9. A method of treating an individual suffering from a disease condition wherein antagonism of NK<sub>1</sub> receptors in combination with SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound

5 according to Claim 1 or an *in vivo*-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.

10. The method according to Claim 8 or 9 for treating conditions selected from hypertension, depression, depression in cancer patients, depression in Parkinson's patients,

10 postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, phobias, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, anorexia nervosa,

15 bulimia nervosa, obesity, chemical dependencies, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, dementia, amnestic disorders, age-related cognitive decline, Parkinson's diseases, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, endocrine

20 disorders, hyperprolactinaemia, vasospasm, spasm of the cerebral vasculature, cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with

25 vascular disorders, in a mammal, preferably a human, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition.

11. The use of a compound according to Claim 1, or an *in vivo*-hydrolysable precursor or

30 a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in the treatment of a disease condition selected from hypertension, depression, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression,

major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, phobias, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, anorexia nervosa, bulimia nervosa, obesity, chemical dependencies, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, dementia, amnestic disorders, age-related cognitive decline, Parkinson's diseases, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, endocrine disorders, hyperprolactinaemia, vasospasm, spasm of the cerebral vasculature, cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders, in a mammal, comprising

10 administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.

15